Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662383 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
A Phase 3 study of Obesity, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT06662383 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 800 participants, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The trial reports 20 study locations across 10 states.
The verdict
NCT06662383, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Retatrutide
Study Locations (20)
Florida
- Encore Medical Research - Hollywood
- Suncoast Research Group - Miami
- Onhealth Research Center - Miami
- Precision Clinical Research - Sunrise
- Einstein Clinical Research - Vero Beach
California
- Mary & Dick Allen Diabetes Center - Newport Beach
- Artemis Institute for Clinical Research - San Diego
- Encompass Clinical Research - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Georgia
- ClinCept Clinical Research - MH - Columbus
- Northeast Georgia Medical Center - Gainesville
- Pivotal Research Solutions - Stonecrest
Connecticut
- Bridgeport Hospital - Bridgeport
- Yale University School of Medicine - New Haven
Arizona
- Medical Advancement Centers of Arizona - Tempe
Colorado
- Lynn Institute of Denver - Aurora
Hawaii
- East-West Medical Research Institute - Honolulu
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06662383
The ClinicalTrials.gov registry entry for NCT06662383 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06662383 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06662383 about?
NCT06662383 is a clinical study titled "A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity". The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
What is the current status of trial NCT06662383?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2024-11-01. Estimated completion is 2026-12.
What conditions does trial NCT06662383 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06662383?
The interventions under investigation include: Tirzepatide (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT06662383?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06662383 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.